Treatment of benign lymphoid hyperplasia of the orbit with rituximab

Hao H. Ho, Aaron Savar, Felipe Samaniego, John Manning, Armen Kasyan, Barbara Pro, Bita Esmaeli*

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Benign lymphoid hyperplasia is a disorder characterized by polyclonal lymphocytic infiltration of orbital tissues, predominantly with B-cells. Rituximab is a monoclonal antibody directed against CD20, a B-cell marker. Two patients with recurrent orbital masses involving the lacrimal glands were treated with rituximab. The diagnosis of benign lymphoid hyperplasia with predominance of CD20 + cells was confirmed in both cases based on a surgical biopsy. Both patients had been previously treated with standard therapies, including high-dose steroids, and one patient had failed external-beam radiation therapy. They both responded well to treatment with intravenous rituximab. Neither patient experienced any side effects associated with rituximab.

Original languageEnglish (US)
Pages (from-to)11-13
Number of pages3
JournalOphthalmic plastic and reconstructive surgery
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2010

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'Treatment of benign lymphoid hyperplasia of the orbit with rituximab'. Together they form a unique fingerprint.

Cite this